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1 Drug description 
Generic/Brand name/ATC code:  
Bevacizumab/Avastin®/L01XC07 
 
Developer/Company:  
Roche Registration Ltd. 
 
Description:  
Bevacizumab (Avastin®) is a recombinant monoclonal antibody that binds to 
vascular endothelial growth factor (VEGF). By inhibiting VEGF receptor bind-
ing, bevacizumab prevents the growth and maintenance of tumour blood ves-
sels [1]. 
Bevacizumab is used for the treatment of different types of cancer and in 
various combinations with other drugs. Adverse events (AEs) associated with 
bevacizumab treatment may be gastrointestinal perforations, fistulae, wound-
healing complications, hypertension, proteinuria, arterial and venous throm-
boembolism, haemorrhage, pulmonary haemorrhage/haemoptysis, congestive 
heart failure, reversible posterior leukoencephalopathy syndrome and neu-
tropenia [2, 3]. 
In patients with metastatic breast cancer, the recommended dose of bevaci-
zumab is 10 mg/kg given once every two weeks or 15 mg/kg given once every 
three weeks as an intravenous (IV) infusion; treatment should be continued 
until progression of the underlying disease or until unacceptable toxicity [3]. 
 
 
 
2 Indication 
Bevacizumab therapy for patients with human epidermal growth factor 2 
(HER2)-negative, locally recurrent or metastatic breast cancer after first-line 
treatment with bevacizumab plus chemotherapy.  
 
 
 
  
bevacizumab inhibits 
growth and 
maintenance of  
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intravenous 
administration 
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of locally recurrent or 
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3 Current regulatory status 
To date, neither the EMA nor the FDA have granted marketing authorisation 
for bevacizumab as second-line therapy for HER2-negative, locally recurrent 
or metastatic breast cancer that has progressed after first-line treatment with 
bevacizumab plus chemotherapy.  
The EMA approved Avastin® for the following indications [3]: 
 treatment of adult patients with metastatic carcinoma of the colon or 
rectum (in combination with fluoropyrimidine-based chemotherapy) 
 first-line treatment of adult patients with metastatic breast cancer (in 
combination with paclitaxel) 
 first-line treatment of adult patients with metastatic breast cancer in 
combination with capecitabine (when other chemotherapy options in-
cluding taxanes or anthracyclines are not considered appropriate) 
 first-line treatment of adult patients with unresectable advanced, met-
astatic or recurrent non-small cell lung cancer other than predomi-
nantly squamous cell histology (in addition to platinum-based chem-
otherapy) 
 first-line treatment of adult patients with advanced and/or metastatic 
renal cell cancer (in combination with interferon alfa-2a) 
 front-line treatment of adult patients with advanced epithelial ovarian, 
fallopian tube, or primary peritoneal cancer (in combination with car-
boplatin and paclitaxel) 
 treatment of adult patients with first recurrence of platinum-sensitive 
epithelial ovarian, fallopian tube or primary peritoneal cancer who 
have not received prior therapy with bevacizumab or other VEGF in-
hibitors or VEGF receptor-targeted agents (in combination with car-
boplatin and gemcitabine) 
 treatment of adult patients with platinum-resistant recurrent epitheli-
al ovarian, fallopian tube, or primary peritoneal cancer who received 
no more than two prior chemotherapy regimens and who have not re-
ceived prior therapy with bevacizumab or other VEGF inhibitors or 
VEGF receptor-targeted agents (in combination with paclitaxel, topo-
tecan, or pegylated liposomal doxorubicin) 
 in February 2015, the Committee for Medicinal Products for Human 
Use (CHMP) adopted a new indication: bevacizumab, in combination 
with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan 
in patients who cannot receive platinum therapy, for the treatment of 
adult patients with persistent, recurrent, or metastatic carcinoma of the 
cervix [4]. 
In December 2014, the EMA granted orphan designation for bevacizumab for 
the treatment of hereditary haemorrhagic telangiectasia [5]. 
In the US, the FDA approved Avastin® for the treatment of [6]:  
 metastatic colorectal cancer, with intravenous 5-fluorouracil-based 
chemotherapy (first- or second-line treatment) 
 metastatic colorectal cancer, with fluoropyrimidine-, irinotecan- or flu-
oropyrimidine-oxaliplatin-based chemotherapy (for second-line treat-
ment) in patients who have progressed on a first-line Avastin®-contain-
ing regimen 
not approved for 
second-line treatment 
of breast cancer  
by the EMA  
not approved for  
breast cancer indication 
by the FDA 
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 non-squamous non-small cell lung cancer, with carboplatin and pac-
litaxel (for first-line treatment) in patients with unresectable, locally 
advanced, recurrent or metastatic disease 
 glioblastoma, as a single agent for adult patients with progressive  
disease following prior therapy 
 metastatic renal cell carcinoma with interferon alfa 
 cervical cancer, in combination with paclitaxel and cisplatin or  
paclitaxel and topotecan in persistent, recurrent, or metastatic disease 
 platinum-resistant, recurrent epithelial ovarian, fallopian tube or pri-
mary peritoneal cancer, in combination with paclitaxel, pegylated lip-
osomal doxorubicin or topotecan. 
In February 2008, the FDA granted accelerated approval for Avastin® for the 
treatment of HER2-negative metastatic breast cancer (in combination with 
paclitaxel in patients who have not received chemotherapy) [7]. In November 
2011, the approval was revoked; the decision was based on a lack of benefit 
considering delay in the growth of tumours that would justify the potential 
risks. Furthermore, there was no evidence that Avastin® would lengthen the 
life of women with breast cancer or would improve their quality of life [8]. 
 
 
 
4 Burden of disease 
Breast cancer develops in the tissues of the breast. Non-invasive breast cancer 
(also termed “carcinoma in situ”) does not spread by metastases; the most 
common type is ductal carcinoma in situ (DCIS). Invasive breast cancer can 
potentially spread outside the breast; the most common type is ductal carci-
noma. Less common types of breast cancer are invasive lobular breast cancer, 
inflammatory breast cancer and Paget’s disease of the breast [9]. 
Locally recurrent breast cancer is defined as cancer that returns to the tissues 
near the original site or scar (chest, breast or skin). It develops when cancer 
cells, which remained in the local area despite treatment, start to grow again. 
Metastatic breast cancer, also termed secondary or advanced breast cancer, 
develops when cells of the primary tumour spread through the lymphatic or 
blood system to other sites of the body. Most common sites of metastasis in 
breast cancer are the bones, liver, lungs and brain [10].  
In Austria, breast cancer is the most common malignancy in women. In 2011, 
5,423 women in Austria were newly diagnosed with breast cancer and the in-
cidence rate was 76.2 (per 100,000 women per year). The mortality rate in 2011 
was 15.9 per 100,000 women [11]. Breast cancer is most common in middle-
aged and older women; median age at diagnosis is 61 years. The relative1 5-
year survival rate for patients with breast cancer is 89.4% [12]. Approximate-
ly 5–10% of breast cancer patients have metastasis at the time of diagnosis; 
approximately one-fifth of these patients will survive 5 years [13]. 
                                                             
1 The relative survival compares the survival of patients diagnosed with cancer with 
the survival of people in the general population who are the same age, race, and sex 
and who have not been diagnosed with cancer.  
FDA revoked 
accelerated approval of 
breast cancer indication 
invasive ductal 
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most common sites of 
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most common 
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In countries where patients have access to breast screening programmes, ab-
normal mammograms indicate the diagnosis of breast cancer more often than 
the occurrence of symptoms [14]. The most common symptom is a lump or 
mass in the breast (which is often painless); less common symptoms are per-
sistent changes to the breast (e.g. thickening, swelling, distortion, tenderness, 
skin irritation, redness, scaliness) or to the mammilla (ulceration, retraction, 
or spontaneous discharge) [15]. 
Symptoms of more advanced locoregional disease include axillary adenopathy 
or skin findings such as erythema, thickening, or dimpling of the overlying 
skin (peau d’orange). In case of metastasis, symptoms depend on the affected 
organs (e.g. bone – back or leg pain, liver – abdominal pain, nausea, jaundice, 
or lungs – shortness of breath or cough) [14]. 
There are numerous risk factors associated with breast cancer. Potentially 
modifiable factors are weight gain after the age of 18 and/or being overweight 
or obese (for postmenopausal breast cancer), the use of menopausal hormone 
therapy (combined estrogen and progestin), physical inactivity, and alcohol 
consumption. There are indications that long-term, heavy smoking may also 
increase the risk for breast cancer, particularly among women who start smok-
ing before their first pregnancy. Furthermore, shift work (particularly at night) 
may be associated with an increased breast cancer risk. Non-modifiable risk 
factors include high breast tissue density, high bone mineral density, type 2 
diabetes mellitus, certain benign breast conditions (e.g. atypical hyperplasia), 
ductal and lobular carcinoma in situ. Prior high-dose radiation to the chest 
for cancer treatment at a young age also increases breast cancer risk. Repro-
ductive risk-increasing factors are a long menstrual history, recent use of oral 
contraceptives or certain contraceptive injections, never having children, and 
having one’s first child after the age of 30 [15]. 
The majority of breast cancer patients are diagnosed by an abnormal mam-
mogram. These patients need to be further examined by means of magnifica-
tion views, spot compression views and/or targeted ultrasonography to estab-
lish the need for tissue sampling or biopsy. In case of clinical suspicion, the 
lesion should be biopsied regardless of image findings (as 10–15% of such 
lesions can be mammographically occult) [16]. 
After the diagnosis of breast cancer (defined by the presence of malignant epi-
thelial cells), the hormone receptor status needs to be determined. Patients 
must be tested for: 
 estrogen receptor (ER) and progesterone receptor (PR) expression: ER 
and PR are prognostic factors for invasive breast cancers; patients who 
are ER- and/or PR-positive are eligible for neoadjuvant or adjuvant 
endocrine therapy 
 overexpression of HER2 receptors: 20% of patients are HER2-positive 
and will benefit from HER2-directed therapy [14]. 
Patients with triple-negative breast cancer (defined by a lack of HER2 over-
expression or amplification and low ER and PR expression) typically have a 
poor prognosis. There is no standard therapy for these patients, and treatment 
options are limited [17]. 
Breast cancer is staged according to the TNM (tumour, nodes and metastases) 
system of the American Joint Committee on Cancer and the Union for Inter-
national Cancer Control (AJCC-UICC) [16]. 
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5 Current treatment 
In patients with isolated, locally recurrent breast cancer, cure is the main ther-
apeutic target. Therefore, the European Society for Medical Oncology (ESMO) 
recommends [13]: 
 the complete excision of the recurrent tumour (if feasible); in patients 
with prior breast-conserving surgery, a mastectomy is recommended 
(III, A)2 
 full-dose radiotherapy to chest wall and regional lymph node areas in 
patients not previously irradiated (III, A) 
 in patients previously irradiated, re-irradiation to limited areas of the 
chest wall (considering the duration of the radiation-free period, in-
tensity of existing late radiation effects and the risk of additional loco-
regional relapse (III, B) 
 the value of “secondary” or “pseudo-adjuvant” systemic treatment is 
not supported by much evidence, the role of chemotherapy in this set-
ting is assessed in ongoing randomised studies (II, B) 
 “pseudo-adjuvant” endocrine therapy is a reasonable option regarding 
the expected benefit and low toxicity (II, B) 
 according to expert’s opinion, “pseudo-adjuvant” trastuzumab is also 
acceptable (particularly in patients without prior trastuzumab). 
In patients with isolated, locally recurrent breast cancer who are not suitable 
for local treatment with curative intent, e.g. patients with inoperable or pre-
viously irradiated tumours, systemic therapies are the mainstay of treatment. 
The decision for the appropriate systemic therapy is made considering tumour 
biology, previous systemic treatments, duration of disease-free interval, pa-
tient co-morbidities and preferences [13]. 
Metastatic breast cancer is an incurable disease [18]. Systemic treatment in-
tends to prolong survival and to improve the quality of life of affected patients 
[19].  
For the treatment of patients with ER-positive, HER2-negative advanced 
breast cancer, the ESMO gives the following recommendations [18]: 
 endocrine therapy is the preferred treatment option for hormone recep-
tor-positive disease, even in patients with visceral disease (unless there 
is endocrine resistance or fast response is needed); LoE: IA3 
 treatment of premenopausal women: ovarian suppression/ablation 
combined with additional endocrine therapy; LoE: IA  
 tamoxifen should be the additional endocrine agent  
(unless tamoxifen resistance); LoE: IB 
 aromatase inhibitors are an option, invariably require ovarian  
suppression/ablation 
                                                             
2 Levels of evidence [I–V] and grades of recommendation [A–E] as used by the ESMO.  
3 Levels of evidence (LoE): IA = strong recommendation, high-quality evidence; IB = 
strong recommendation, moderate-quality evidence; IC = strong recommendation, 
low-quality evidence. 
ESMO 
recommendations  
for locally recurrent 
breast cancer 
metastatic breast cancer 
is incurable  
 
 
ESMO 
recommendations for 
advanced breast cancer 
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 optimal post-aromatase inhibitor treatment is uncertain; tamoxifen, 
another aromatase inhibitor (with different mechanism of action), high-
dose (HD) fulvestrant, megestrol acetate and everolimus plus aroma-
tase inhibitor are available options; LoE: IA 
 maintenance endocrine therapy (after chemotherapy) is a reasonable 
option to maintain the benefit (method not assessed in randomised tri-
als); LoE: IC 
 concomitant chemotherapy and endocrine therapy should not be ap-
plied outside of a clinical trial (this combination has not shown a sur-
vival benefit); LoE: IB 
 treatment of postmenopausal women: depending on type and duration 
of adjuvant endocrine therapy, preferred first-line endocrine therapy 
is an aromatase inhibitor or tamoxifen; LoE: IA 
 fulvestrant HD is also an option; LoE: IB 
 for some postmenopausal women with disease progression after a non-
steroidal aromatase inhibitor, the addition of everolimus to an aroma-
tase inhibitor is a valid treatment option; however, the toxicities as-
sociated with this therapy need to be weighed against the benefits of 
significant PFS prolongation and survival prolongation (which is not 
statistically significant). 
The American Society for Clinical Oncology (ASCO) [20] also recommends 
endocrine therapy as the standard first-line treatment in women with hor-
mone receptor-positive, advanced or metastatic breast cancer4, as it provides 
less toxicity and better quality of life when compared with chemotherapy. 
Patients with recurrent or metastatic breast cancer at diagnosis are stratified 
according to the presence of bone metastasis [19]. In women with bone metas-
tasis, the administration of intravenous bisphosphonates (in addition to chem-
otherapy or endocrine therapy) is a palliative care measure without proven 
impact on overall survival. Patients’ benefits from bisphosphonate treatment 
are fewer skeletal-related events, fewer pathologic fractures and less need for 
radiation therapy and surgery to treat bone pain. Denosumab may me an-
other treatment option for patients with metastatic breast cancer to bone; the 
agent was shown to significantly delay time to the first skeletal-related event 
in a single randomised trial. However, the optimal duration of denosumab 
treatment and long-term risks are unknown [19]. 
 
 
 
  
                                                             
4 Except for immediately life-threatening disease or concern regarding endocrine  
resistance. 
treatment options for 
bone metastasis 
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6 Evidence 
A literature search was conducted on 20 February 2015 in four databases (The 
Cochrane Library, CRD Database, Embase, Medline). Search terms were “Be-
vacizumab”, “Avastin”, “Altuzan”, “nsc 704865”, “breast cancer”, “breast neo-
plasms”, “epidermal growth factor receptor 2”, “HER2”, “metastasis”. Also, 
when contacted for any further evidence, the manufacturer submitted 4 ref-
erences.  
Overall, 640 references were identified. Included in this report are: 
 1 phase III study, comparing bevacizumab plus chemotherapy versus 
chemotherapy alone as second-line treatment for patients with HER2-
negative locally recurrent or metastatic breast cancer after first-line 
treatment with bevacizumab plus chemotherapy (TANIA trial) [21] 
 1 randomised, open-label phase III trial assessing maintenance cape-
citabine and bevacizumab versus bevacizumab alone after initial first-
line bevacizumab and docetaxel for patients with HER2-ngeative met-
astatic breast cancer (IMELDA trial) [22]. 
 
 
6.1 Efficacy and safety – phase III studies 
Table 1: Summary of efficacy 
Study title  
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative 
locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): 
an open-label, randomised phase III trial [21]. 
Study 
identifier 
NCT01250379, EudraCT Number 2010-020998-16 
Design Open-label, parallel-group, randomised (1:1 ratio), multicentre (118 centres in 12 countries), ongoing 
Duration  Enrolment: 2011-02-17 to 2013-04-03 
Median follow-up: 16.1 months (combination group),  
15.9 months (chemotherapy-alone group) 
Cut-off dates for analyses: 2013-12-20 (primary analysis of PFS),  
2015-04 (final data collection date for primary outcome measure) 
Hypothesis Superiority 
For the primary analysis, second-line PFS events were required in 384 of 488 patients for 80% power with 
a two-sided ∝ of 0.05. Progression-free survival was compared between treatment groups with a two-sided 
log-rank test, stratified by stratification factors. Median progression-free survival was estimated by the 
Kaplan-Meier method. A stratified Cox proportional hazards model was used to estimate HRs and 95% CIs. 
Funding F Hoffmann-La Roche 
Treatment 
groups 
Intervention 
(n=247) 
Second-line single-agent chemotherapy plus bevacizumab  
(15 mg/kg every 3 weeks or 10 mg/kg every 2 weeks) 
Control 
(n=247) 
Second-line single-agent chemotherapy at the investigators’ discretion ((nanoparticle 
albumin-bound) paclitaxel, docetaxel, capecitabine, gemcitabine, ((non-)pegylated 
liposomal) doxorubicin, epirubicin, vinorelbine, cyclophosphamide, ixabepilone) 
Endpoints 
and 
definitions 
PFS 
(primary outcome) 
PFS Time from randomisation to disease progression or death on second-line 
treatment 
PFS in stratification 
subgroups 
- Assessed in prespecified stratification subgroups (hormone receptor status, 
first-line PFS, selected second-line chemotherapy, LDH concentration) 
PFS  - From randomisation until disease progression or death on third-line therapy 
640 references in total, 
2 phase III studies were 
included 
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Endpoints 
and 
definitions 
(continuation) 
Objective  
response rate 
ORR Defined as complete or partial tumour response. 
Tumour assessment was based on limited Response Evaluation Criteria  
in Solid Tumours (RECIST) version 1.1; no independent review of tumour 
assessment was done 
Overall survival  OS From randomisation to death from any cause 
1-year overall 
survival 
- Defined as the number of patients alive 1 year after randomisation 
Safety - Assessed using Common Terminology Criteria for Adverse Events (version 4.0) 
Patient-reported 
outcomes 
- Assessed with the Functional Assessment of Cancer Therapy – Breast 
questionnaire (FACT-B) 
Results and analysis 
Analysis  
description 
Efficacy analysed in the intention-to-treat population 
Safety analysed in all patients who received at least one dose of study therapy  
(bevacizumab or chemotherapy, safety population) 
Analysis  
population 
Inclusion  Age ≥ 18 years 
 HER2-negative, measurable or non-measurable, locally recurrent or 
metastatic breast cancer 
 Disease had to have progressed (according to investigator assessment) after 
12 weeks or more of first-line bevacizumab plus chemotherapy for locally 
recurrent or metastatic breast cancer  
 Maintenance bevacizumab, maintenance endocrine therapy, or both, before 
enrolment was allowed  
 ECOG performance status 0–2 
 An estimated life expectancy of 12 weeks or more 
Exclusion  Previous first-line anti-angiogenic therapy (except bevacizumab) for locally 
recurrent or metastatic breast cancer 
 Positive or unknown HER2 status 
 Inadequately controlled hypertension 
 A history of nephrotic syndrome, hypertensive crisis, hypertensive 
encephalopathy, bleeding diathesis, clinically relevant coagulopathy,  
or grade-3 or -4 venous thromboembolism 
 A history of myocardial infarction, unstable angina, significant vascular disease, 
gastrointestinal perforation, abdominal fistula, intraabdominal abscess, or 
active gastrointestinal bleeding within 6 months preceding study treatment 
 Known CNS disease (except treated brain metastases) 
Characteristics  Chemotherapy 
+ bevacizumab 
Chemotherapy 
alone 
Median age (range), years  56 (24–81) 54 (30–77) 
Hormone receptor status, % 
Triple-negative 
ER or PgR-positive or both positive 
 
20 
80 
 
23 
76 
Locally recurrent or metastatic disease at  
first diagnosis, % 
15 20 
Disease-free interval, % 
≤ 12 months 
≤ 24 months 
 
7 
21 
 
10 
23 
Previous (neo)adjuvant chemotherapy, % 
Taxane 
Anthracycline 
Other 
 
40 
63 
66 
 
39 
56 
58 
Previous (neo)adjuvant bevacizumab, % 2 1 
Previous endocrine therapy for locally 
recurrent/metastatic breast cancer, % 
51 45 
Timing of first-line progression in relation to 
first-line chemotherapy plus bevacizumab, % 
During bevacizumab 
After bevacizumab 
Unknown/missing/other 
 
 
18 
79 
2 
 
 
19 
80 
<1 
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Analysis  
population 
(continuation) 
Characteristics 
(continuation) 
Invasive ductal, % 81 83 
Invasive lobular, % 15 12 
Metastatic organ sites at baseline, % 
Visceral 
Liver 
Lung 
≥ 3 metastatic organ  
sites 
Bone only 
 
75 
58 
28 
32 
 
6 
 
77 
61 
30 
36 
 
6 
First-line chemotherapy with bevacizumab, % 
Paclitaxel 
Docetaxel 
Capecitabine 
 
74 
13 
16 
 
73 
11 
19 
First-line PFS 
Median, months (IQR) 
< 6 months (%) 
≥ 6 months (%) 
 
14.9 (9.2–24.3) 
10 
89 
 
14.1 (8.5–23.3) 
13 
86 
History of hypertension, % 57 47 
Bevacizumab-free interval before  
study therapy, % 
≤ 6 weeks  
> 6 weeks 
Missing 
 
 
60 
40 
0 
 
 
67 
33 
<1 
LDH concentration, % 
≤ 1.5 x ULN 
> 1.5 x ULN 
 
85 
15 
 
84 
16 
Descriptive 
statistics 
and 
estimated 
variability 
 
Treatment group 
Intervention (chemotherapy 
plus bevacizumab) 
Control  
(chemotherapy alone) 
Number of subjects N=247 N=247 
PFS Median (95% CI), months 6.3 (5.4–7.2) 4.2 (3.9–4.7) 
Objective response, number (%) 
CR 
PR 
SD 
PD 
38 (21) 
1 (<1) 
37 (20) 
89 (49) 
44 (24) 
31 (17) 
2 (1) 
29 (16) 
62 (34) 
76 (41) 
Duration of response  
median (95% CI), months 
8.3 (6.1–10.3) 10.6 (4.4–16.7) 
Effect 
estimate 
per 
comparison 
 
Comparison groups 
 Chemotherapy + bevacizumab 
vs. Chemotherapy alone 
PFS Stratified HR 0.75 
95% CI 0.61–0.93 
P value 0.0068 
Unstratified HR 0.77 
95% CI 0.63–0.93 
ORR Absolute difference, % 4.1 
95% CI -4.2–12.4 
P value 0.35 
Abbreviations: CI =confidence interval, CNS = central nervous system, CR = complete response, EGOC = Eastern Cooperative 
Oncology Group, ER = estrogen receptor, HER2 = human epidermal growth factor 2, HR = hazard ratio, IQR = inter-
quartile range, LHD = lactate dehydrogenase, OR = objective response, OS = overall survival, PD = progressive disease, 
PFS = progression-free survival, PgR = progesterone receptor, PR = partial response, SD = stable disease, ULN = upper limit 
of normal 
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Table 2: Most frequent adverse events5 
Adverse Event 
(according to CTCAE 
version 4.0) 
Chemotherapy plus bevacizumab 
(n=245) 
Chemotherapy alone  
(n=238) 
 
Grades 1–2 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Grade 5 
n (%) 
Grades 1–2 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Grade 5 
n (%) 
Neutropenia 8 (3) 17 (7) 12 (5) 0 13 (5) 13 (5) 7 (3) 0 
Anaemia 11 (4) 5 (2) 0 0 5 (2) 2 (<1) 0 0 
Thrombocytopenia 7 (3) 2 (<1) 3 (1) 0 1 (<1) 1 (<1) 0 0 
Febrile Neutropenia 0 4 (2) 4 (2) 0 0 0 4 (2) 0 
Proteinuria 96 (39) 17 (7) 0 0 51 (21) 1 (<1) 0 0 
Hypertension 36 (15) 33 (13) 0 0 25 (11) 17 (7) 0 0 
Haemorrhage 19 (8) 0 0 0 6 (3) 0 1 (<1) 0 
Hand-foot syndrome 35 (14) 27 (11) 0 0 25 (11) 25 (11) 0 0 
Fatigue 24 (10) 8 (3) 0 0 20 (8) 8 (3) 0 0 
Mucosal inflammation 13 (5) 4 (2) 0 0 4 (2) 1 (<1) 0 0 
Diarrhoea 19 (8) 7 (3) 0 0 20 (8) 8 (3) 0 0 
Nausea 22 (9) 4 (2) 0 0 18 (8) 6 (3) 0 0 
Vomiting 9 (4) 3 (1) 0 0 18 (8) 3 (1) 0 0 
Dyspnoea 4 (2) 0 0 0 2 (<1) 4 (2) 1 (<1) 0 
Pulmonary embolism 1 (<1) 3 (1) 2 (<1) 0 0 4 (2) 0 0 
Increased GGT 0 8 (3) 2 (<1) 0 0 5 (2) 1 (<1) 0 
Increased AST 2 (1) 5 (2) 0 0 1 (<1) 2 (<1) 0 0 
Hyponatraemia 1 (<1) 4 (2) 1 (<1) 0 1 (<1) 1 (<1) 0 0 
Abbreviations: AE = adverse event, AST = aspartate aminotransferase, CTC = Common Terminology Criteria for Adverse 
Events, GGT = gamma glutamyltransferase 
 
Table 3: Adverse events of special interest for bevacizumab (second-line safety population) 
Adverse events  
(according to CTCAE version 4.0) 
Chemotherapy plus bevacizumab 
(n=245) 
Chemotherapy alone  
(n=238) 
 All grades Grade ≥ 3 All grades Grade ≥ 3 
Hypertension 69 (28) 33 (13) 42 (18) 17 (7) 
Bleeding 32 (13) 1 (<1) 14 (6) 4 (2) 
Proteinuria 113 (46) 17 (7) 52 (22) 1 (<1) 
Thromboembolic event 
Venous 
Arterial 
21 (9) 
21 (9) 
0 
8 (3) 
8 (3) 
0 
11 (5) 
7 (3) 
4 (2) 
8 (3) 
5 (2) 
3 (1) 
Febrile neutropenia 8 (3) 8 (3) 4 (2) 4 (2) 
Congestive heart failure 5 (2) 5 (2) 1 (<1) 1 (<1) 
Wound-healing complication 4 (2) 2 (<1) 1 (<1) 0 
Fistula or abscess 1 (<1) 0 2 (<1) 0 
Gastrointestinal perforation 2 (<1) 1 (<1) 0 0 
Abbreviation: CTCAE = Common Terminology Criteria for Adverse Events 
                                                             
5 AEs occurring at any grade in more than 5% of patients or grade 3 or greater in more than 2% of patients in the 
second-line therapy safety population. 
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The TANIA trial [21] assesses the effect of second-line bevacizumab after dis-
ease progression on or after first-line bevacizumab plus chemotherapy in lo-
cally recurrent or metastatic HER2-negative breast cancer. This open-label, 
parallel-group, randomised multicentre phase III trial was ongoing until April 
2015. A total of 494 patients were randomly assigned (1:1) to receive second-
line single-agent chemotherapy at the investigators’ discretion either alone 
(n=247) or with bevacizumab (n=247). Neither patients nor investigators 
were masked to treatment assignment. The patients were stratified according 
to hormone receptor status, first-line progression-free survival (PFS), selected 
second-line chemotherapy and lactate dehydrogenase concentration (LDH). 
Neither patients nor investigators were masked to treatment assignment. 
The patients had a median age of 56 and 54 years in the chemotherapy-plus-
bevacizumab group and in the chemotherapy-alone group respectively. 32% 
in the combination arm and 36% of patients in the chemotherapy-alone arm 
had ≥ 3 metastatic organ sites and 20% and 23% had triple-negative disease 
respectively, and in both groups the majority had hormone receptor-positive 
disease (>76%).  
Previous (neo)adjuvant bevacizumab was administered in 2% of patients in the 
combination arm and in 1% of patients in the chemotherapy-alone arm. But 
all patients had experienced disease progression after 12 weeks or more of first-
line bevacizumab plus chemotherapy. About 80% of patients progressed after 
first-line bevacizumab therapy, and 67% in the chemotherapy-alone group in 
comparison to 60% in the combination arm had a bevacizumab-free interval 
of ≤ 6 weeks. (Neo)adjuvant chemotherapy consisted of a taxane in 40%/39% 
of patients, 63%/56% of patients received anthracycline, 66%/58% of patients 
were treated with other agents in the chemotherapy-plus-bevacizumab group 
and the chemotherapy-alone group respectively. 51% of patients in the chem-
otherapy-plus-bevacizumab group and 45% in the chemotherapy-alone group 
had received previous endocrine therapy for locally recurrent or metastatic 
breast cancer. In the combination arm, 74% of patients had received first-line 
chemotherapy with bevacizumab with paclitaxel, 13% with docetaxel and 16% 
with capecitabine. In the chemotherapy-alone group, first-line chemotherapy 
with bevacizumab was administered with paclitaxel in 73% of patients, with 
docetaxel in 11% and with capecitabine in 19% of patients.  
From prespecified standard options, the investigators chose single-agent chem-
otherapy for each patient: paclitaxel (IV), nanoparticle albumin-bound pac-
litaxel (IV), docetaxel (IV), capecitabine (orally), gemcitabine (IV), pegylated 
liposomal doxorubicin (IV), non-pegylated liposomal doxorubicin (IV), dox-
orubicin (IV), epirubicin (IV), vinorelbine (IV or orally), cyclophosphamide 
(IV or orally) or ixabepilone (IV). Second-line chemotherapy was continued 
until disease progression, unacceptable toxicity or patient withdrawal. De-
pending on the selected chemotherapy regimen, patients received bevacizum-
ab at a dosage of 15 mg/kg every three weeks or 10 mg/kg every two weeks. 
In case of toxicity, dose reduction or dose modifications were not allowed. 
Median follow-up was 16.1 months in the chemotherapy-plus-bevacizumab 
group and 15.9 months in the chemotherapy-alone group, measured at the da-
ta cut-off for the primary analysis of PFS. The median duration of second-line 
chemotherapy was 4.4 months in the combination group versus 3.9 months in 
the chemotherapy-alone group. The median duration of bevacizumab treat-
ment was 4.5 months and the median duration of single-agent bevacizumab 
after termination of chemotherapy was 1.7 months. At the time of data cut-off, 
second-line therapy was ongoing in 7% of patients of each group; 5% (com-
efficacy and safety  
of second-line 
chemotherapy plus 
bevacizumab was 
assessed in 494 patients 
all patients had  
disease progression after 
first-line bevacizumab 
plus chemotherapy 
the majority of patients 
received paclitaxel  
(plus bevacizumab)  
as first-line therapy 
second-line 
chemotherapy 
with/without 
bevacizumab 
median duration of 
bevacizumab treatment 
was 4.5 months 
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bination group)/6% (chemotherapy-alone group) of patients changed chem-
otherapy regimen before disease progression. 12% of combination group pa-
tients, compared to 7% of chemotherapy-alone group patients switched to en-
docrine treatment during second-line therapy before disease progression.  
The primary endpoint of the TANIA trial was second-line PFS. Median PFS 
was 6.3 months (95% CI 5.4–7.2)6 in the chemotherapy-plus-bevacizumab 
group versus 4.2 months (3.9–4.7) in the chemotherapy-alone group. Strati-
fied hazard ratio (HR) was 0.75 (95% CI 0.61–0.93), two-sided, stratified log-
rank p=0.0068; unstratified HR was 0.77 (95% CI 0.63–0.93). According to 
the authors (data was not provided), analyses of HRs in predefined explora-
tory subgroups were very similar to the HR in the intention-to-treat popula-
tion, except for some of the smallest subgroups including less than 50 patients 
with wide 95% CIs. 
Rates of objective responses to second-line therapy (a secondary endpoint) 
were 17% in the chemotherapy-alone group and 21% in the chemotherapy-
plus-bevacizumab group (4.1% absolute difference, 95% CI -4.2–12.4, p=0.35).  
In the combination arm, < 1% of patients achieved complete response and 
20% achieved partial response. Among the chemotherapy-alone group pa-
tients, 1% of patients achieved complete, and 16% partial response. 40% of 
patients receiving chemotherapy plus bevacizumab and 41% of patients re-
ceiving chemotherapy alone had died at the time of data cut-off; overall sur-
vival (OS) results are immature. The most common cause of death in both 
groups was disease progression or breast cancer. 
Adverse events (AEs) of grade 3 or worse occurred in 59% of combination-
group patients and in 46% of patients who received chemotherapy alone. Hy-
pertension of grade ≥ 3 was reported from 13% (combination group) vs. 7% 
(chemotherapy-alone group) of patients; proteinuria of grade ≥ 3 occurred in 
7% (combination group) vs. ≤ 1% (chemotherapy-alone group) of patients. 
The death of 2% of patients in each group (during second-line therapy and 
beyond) in the safety population (n=438) was attributed to AEs; causes of 
death were pancreatitis, cerebrovascular disorder, cardiac failure, cardiotox-
icity and sudden death. Serious AEs occurred in 25% of chemotherapy-plus-
bevacizumab group patients compared to 18% of chemotherapy-alone patients. 
Due to the occurrence of AEs (most commonly proteinuria, venous and pul-
monary embolism), 18% of patients discontinued second-line bevacizumab 
treatment. 16% of combination group patients versus 8% of chemotherapy-
alone group patients discontinued chemotherapy because of AEs. Chemother-
apy doses were reduced in 47% (combination group) and 37% (chemotherapy-
alone group) of patients respectively. 
 
  
                                                             
6 CI = confidence interval 
PFS was significantly 
longer in patients of 
combination group 
4.1% absolute difference 
in objective response 
between the groups 
AEs of grade 3 or worse 
in 59% (combination 
group) and 46% 
(chemotherapy-alone 
group) 
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6.2 Efficacy and safety – further studies 
The IMELDA trial [22], a randomised, open-label, phase III trial, compared 
the administration of maintenance capecitabine and bevacizumab versus be-
vacizumab alone after initial first-line bevacizumab and docetaxel. 284 pa-
tients were eligible, having HER2-negative metastatic breast cancer with at 
least one measurable lesion (according to Response Evaluation Criteria in Sol-
id Tumours, RECIST, version 1.0). Included patients had a median age of 54 
(bevacizumab only) and 49 (bevacizumab and capecitabine) years respectively. 
Hormone receptor status was triple negative in 22% of patients in the bevaci-
zumab-only group and 27% in bevacizumab-and-capecitabine group patients. 
78% of bevacizumab-only patients and 73% of bevacizumab-and-capecitabine 
patients were ER- or PR-positive or both. 57% of patients in the bevacizumab-
only group and 47% of patients in the bevacizumab-plus-capecitabine group 
had ≥ 3 metastatic organs at baseline. 
Initially, patients received up to six cycles of bevacizumab (15 mg/kg) and 
docetaxel (75–100 mg/m2) on day 1 every three weeks. Patients who achieved 
stable disease or a complete or partial response were randomly assigned to re-
ceive bevacizumab alone (15 mg/kg, once every three weeks) or bevacizumab 
at the same dosage combined with capecitabine (1000 mg/m2 twice daily on 
days 1–14, every three weeks). The median treatment duration in the mainte-
nance phase was 3.5 months in the bevacizumab only-group and 8.3 months 
in patients who received bevacizumab plus capecitabine. Patients received a 
median of 6 cycles of bevacizumab (bevacizumab-only group) compared to a 
median of 12 cycles (bevacizumab-plus-capecitabine group). 
In patients of the bevacizumab-plus-capecitabine group, PFS was significantly 
improved compared to PFS in patients of the bevacizumab-only group: me-
dian 11.9 months (95% CI 9.8–15.4) versus 4.3 months (95% CI 3.9–6.8), 
stratified HR 0.38, 95% CI 0.27–0.55, two-sided log-rank p < 0.0001; results 
were consistent with those for time to progression. Median OS was 23.7 
months (bevacizumab-only group) versus 39.0 months (bevacizumab-plus-
capecitabine group), resulting in a stratified HR of 0.43, 95% CI 0.26–0.69, 
two-sided log-rank p = 0.0003. 1-year OS was 72% for patients receiving 
bevacizumab only compared to 90% of patients receiving bevacizumab plus 
capecitabine. Objective response was achieved by 77% (bevacizumab only) 
and 86% (bevacizumab plus capecitabine) of patients respectively (difference: 
9.2 percentage points, 95% CI -2.1–20.3, p=0.11). Clinical benefit was report-
ed in 98% of patients in the bevacizumab-only group and 99% in the bevaci-
zumab-plus-capecitabine group. 
During the initial phase, AEs occurred in 50% (grade 3), 15% (grade 4) and 
2% (grade 5) of patients, the most common grade being 3 or worse AEs were 
haematological. During the maintenance phase, grade 3 or worse AEs occur-
red in 27% (bevacizumab only) and 49% (bevacizumab plus capecitabine) of 
patients respectively. Due to an AE, one patient in each group died during 
the maintenance phase, caused by acute coronary syndrome (bevacizumab-
only group) and renal failure (bevacizumab-plus-capecitabine group). Serious 
AEs occurred in 8% of patients in the bevacizumab-only group and in 11% 
of patients in the bevacizumab-plus-capecitabine group.  
It should be noted that recruitment for this study was terminated premature-
ly. Some centres stopped accrual or withdrew patients from study treatment 
as a result of the withdrawn approval of bevacizumab-plus-docetaxel combi-
nation therapy.  
phase III trial comparing 
maintenance 
capecitabine with or 
without bevacizumab 
initial phase: 
bevacizumab plus 
docetaxel 
 
maintenance phase: 
bevacizumab alone or 
bevacizumab plus 
capecitabine 
PFS significantly 
improved in patients 
receiving bevacizumab 
plus capecitabine  
 
median OS prolonged in 
combination group, but 
no significance 
higher incidence of 
grade 3 or worse AEs in 
combination group 
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7 Estimated costs 
In patients with metastatic breast cancer, the recommended dose of bevaci-
zumab is 10 mg/kg IV given once every two weeks or 15 mg/kg IV given once 
every three weeks [3]. Bevacizumab (Avastin®) is available in vials of 4 ml 
(25 mg/ml) at € 414.05 and vials of 16 ml (25 mg/ml) at € 1,421.90 [23]. As-
suming a dosage schedule of 10 mg/kg and an average body weight of 70 kg, 
costs for one dose of bevacizumab are approximately € 2,664.05 (using 1 vial 
of 16 ml and 3 vials of 4 ml).  
The median duration of patients in the TANIA trial [21] who received chem-
otherapy plus bevacizumab was 4.5 months. In patients participating in the 
IMELDA trial [22], bevacizumab was administered at a median of 6 cycles 
(maintenance phase, bevacizumab-only group). Assuming a treatment dura-
tion of 20 weeks with a total of 10 intravenous infusions of bevacizumab, costs 
for bevacizumab treatment are approximately € 26,665. Additionally, costs 
for chemotherapy and the management of potentially occurring AEs incur. 
 
 
 
8 Ongoing research 
In April 2015, a search in databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu  was conducted. The following phase III trials, 
evaluating the use of bevacizumab in combination regimens in advanced 
lines of therapy, were identified: 
 NCT01935492 (EudraCT Number: 2010-021519-18): An open, random-
ised phase III study, comparing 8 continuous cycles of chemotherapy 
with 8 cycles of intermittent (2 times 4 cycles) chemotherapy in first-
line treatment, in combination with bevacizumab, and second-line 
treatment of patients with HER2/neu-negative, incurable, metastatic 
or unresectable, locally advanced breast cancer. The estimated study 
completion date is October 2019. 
 NCT00601900: Assessing endocrine therapy with or without anti-VEGF 
therapy for women with hormone receptor-positive advanced breast 
cancer in a randomised phase III trial. The study is ongoing, primary 
completion date was June 2014.  
Bevacizumab, combined with chemotherapeutic agents for the treatment of 
advanced breast cancer, is currently also under investigation in phase II trials: 
 NCT02175446 (EudraCT Number: 2013-003194-10): A phase II single-
arm study evaluating the efficacy and safety of eribulin in combination 
with bevacizumab for the second-line treatment of HER2-negative met-
astatic breast cancer progressing after first-line therapy with bevacizu-
mab and paclitaxel. Estimated study completion date is December 2016. 
 NCT01989780: Bevacizumab plus paclitaxel optimisation study with 
interventional maintenance endocrine therapy in advanced or metastat-
ic ER-positive HER2-negative breast cancer (BOOSTER trial, multi-
centre, randomised phase II). Estimated study completion date is March 
2017. 
one dose of Avastin® 
costs approx. € 2,664  
costs for  
ten treatment cycles: 
approx. € 26,665 
2 phase III trials and  
2 phase II trials were 
identified 
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There are numerous studies ongoing, evaluating bevacizumab alone or in 
combination therapy for different types of cancer, such as renal cell carci-
noma, glioma, sarcoma, melanoma, oesophageal or gastric cancer. 
 
 
 
9 Commentary 
Bevacizumab (Avastin®) is indicated in different types of cancer and in vari-
ous combinations with other drugs. To date, bevacizumab has not been 
approved either by the EMA or the FDA for the second-line treatment of pa-
tients with HER2-negative, locally recurrent or metastatic breast cancer after 
first-line treatment with bevacizumab plus chemotherapy, which corresponds 
to the indication investigated by the TANIA trial [21] comparing second-line 
single-agent chemotherapy either alone or with bevacizumab in a total of 494 
patients.  
As regards breast cancer, bevacizumab is approved by the EMA for the first-
line treatment of patients with metastatic breast cancer in combination with 
paclitaxel or capecitabine [3]. In 2010, the CHMP concluded that the combi-
nation therapy of Avastin® and docetaxel for metastatic breast cancer (which 
was approved in 2009) should no longer be used. The decision was based on a 
negative benefit/risk balance [24]. In 2008, the FDA granted accelerated ap-
proval for bevacizumab for the treatment of metastatic HER2-negative breast 
cancer in combination with paclitaxel in patients who have not received chem-
otherapy [7]. The approval has been revoked in November 2012, based on a 
lack of benefit regarding delay in tumour growth and evidence for bevacizu-
mab to improve life expectancy and quality of life of patients [8].  
In the TANIA trial, analyses of PFS showed a median gain of 2.1 months for 
patients receiving further bevacizumab, resulting in a risk reduction for pro-
gression or death by any cause of 25%. Findings of PFS improvement induced 
by bevacizumab are similar to the results of the RIBBON-2 trial [25]. The 
phase III trial evaluated the addition of bevacizumab to second-line chemo-
therapy in patients with locally recurrent or HER2-negative metastatic breast 
cancer; however, patients in the RIBBON-2 trial did not receive bevacizumab 
for first-line treatment. Median PFS increased from 5.1 to 7.2 months, strati-
fied HR was 0.78 (95% CI 0.64–0.93, p = 0.0072). In the IMELDA study [22], 
PFS and OS were significantly longer in patients receiving maintenance be-
vacizumab and capecitabine than in those who received maintenance bevaci-
zumab alone.  
Since maintenance therapy following first-line bevacizumab was allowed in 
the TANIA trial, the majority of patients had a bevacizumab-free interval be-
fore study treatment of ≤ 6 weeks. The proportion of patients receiving be-
vacizumab as maintenance treatment rather than as second-line therapy, how-
ever, remains unknown. Thus, it is unclear whether bevacizumab first-line ± 
maintenance therapy following disease progression or bevacizumab second-
line therapy either with or without previous bevacizumab therapy yields bet-
ter results. In addition, even though endocrine therapy is the preferred treat-
ment option for ER-positive, HER2-negative advanced breast cancer patients 
[18], only about 50% of the patients had received previous endocrine therapy 
in the TANIA trial. This raises the question whether patients included were 
initially undertreated.  
numerous phase II 
studies assessing 
bevacizumab in various 
cancer types 
neither approved by  
the EMA nor the FDA for 
second-line treatment 
of breast cancer 
TANIA trial:  
PFS significantly 
improved 
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The objective response rate in the TANIA study was, with an absolute differ-
ence of 4.1%, slightly higher in the combination group than in the chemo-
therapy-alone group. Since 41% of patients in the chemotherapy-alone group 
and 40% in the combination group had died at the time of data cut-off, OS 
results were immature [21]. 
Results from a systematic review [26] evaluating the efficacy in bevacizumab 
in breast cancer (first-/second-line setting), including 14 phase III trials with 
a total of 4,400 patients with metastatic breast cancer, also showed increased 
response rates in PFS but “no trial demonstrated an OS benefit”. In contrast, 
results of the IMELDA trial showed longer median OS in patients receiving 
bevacizumab plus capecitabine [22].  
In the TANIA trial, the incidence of AEs of grade 3 or worse was more fre-
quent in patients of the combination group (59%) than in patients of the 
chemotherapy-alone group (46%). Serious AEs also occurred more frequently 
in the combination group (25%) than in the chemotherapy-alone group (18%). 
These findings concerning AEs are supported by the results of a meta-analysis 
of randomised controlled trials [27], including a total of 6,436 patients show-
ing that, in patients with advanced cancer, bevacizumab treatment was asso-
ciated with a slightly higher risk for any severe AE (grade 3 or 4). The death 
of 2% of patients in each group of the TANIA trial was attributed to AEs. 
These results are similar to those of a meta-analysis [28] assessing treatment-
related mortality with bevacizumab in cancer patients (overall incidence of 
fatal AEs with bevacizumab was 2.9%, 95% CI, 2.0–4.2%). 
According to the ESMO guidelines [18], bevacizumab combined with chem-
otherapy as first- or second-line therapy for metastatic breast cancer provides 
“only a moderate benefit in PFS and no benefit in OS”. Due to the absence of 
known predictive factors for bevacizumab, recommendations on its use are 
problematic. Therefore, bevacizumab is only considered as an option in se-
lected cases and it is “not recommended after a first/second line”. Similarly, 
according to the National Comprehensive Cancer Network (NCCN) breast 
cancer guidelines [19], a series of trials in patients with metastatic breast can-
cer showed a modest increase of PFS with bevacizumab (mainly in combina-
tion with paclitaxel), but none of these studies demonstrated an increase in 
OS or quality of life.  
The ASCO [20] recommends to consider bevacizumab with single-agent chem-
otherapy only in case of immediately life-threatening disease or severe symp-
toms (moderate strength of recommendation). The potential moderate benefit 
of the treatment (improved disease control) faces the high potential harms 
(unique toxicity, increased costs and barriers to access). 
In light of these facts, the additional value of bevacizumab in second-line 
treatment is uncertain. Furthermore, there are indications that the addition 
of bevacizumab to chemotherapy (paclitaxel) in patients with HER2-negative 
metastatic breast cancer is not cost-effective [29]. Thus, the increased costs 
of adding bevacizumab to chemotherapy have to be considered and weighed 
against patients’ benefits. 
Since the TANIA trial is the only phase III trial evaluating this particular in-
dication and it is debatable whether the results (PFS and/or AEs) may have 
been influenced by the open-label design of the study (patients and investiga-
tors were not masked to treatment assignment), further evidence is required. 
Additionally, information regarding patients’ quality of life is of utmost im-
portance since the aim of therapy is palliation of symptoms and improvement 
immature OS results 
higher incidence of AEs 
in combination group 
the ESMO considers 
bevacizumab as an 
option only in  
selected cases 
further research  
is required 
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of quality of life. Although patient-reported outcomes were assessed in the 
TANIA trial, using the Functional Assessment of Cancer Therapy – Breast 
questionnaire, the results were not available yet.  
Future trials should include identification of robust predictive biomarkers in 
order to improve our understanding of molecular biomarkers and mechanisms 
[26]. Recently, two potential predictive biomarkers (circulating VEGF and 
tumour neuropilin-1 expression) were identified; however, a prospective trial, 
randomising or stratifying patients based on VEGF levels to standard thera-
py is required to validate the results [30]. Since the investigations were made 
among patients with advanced or metastatic gastric cancer, the applicability 
of these results to other tumour types is unclear. 
Moreover, it will be important to investigate mechanisms of resistance to anti-
angiogenic therapy [31]. A possible explanation for bevacizumab’s lack of im-
pact on OS may be that anti-VEGF therapy (despite initial tumour growth 
suppression) could lead to rapid changes in the biology of metastatic breast 
cancer that limits the ability of the therapy to improve survival. The exist-
ence of alternative VEGF-independent mechanisms of tumour vascularisation, 
such as vessel co-option (tumours grow along existing blood vessels), may be 
another reason. Further trials are needed to investigate how VEGF pathway 
suppression affects the biology of breast cancer [32]. 
In conclusion, the addition of bevacizumab to standard second-line chemo-
therapy provides only modest benefits for patients with locally recurrent or 
metastatic breast cancer. No improvement in relevant outcomes such as OS 
was ascertained; hence, there is no evidence that bevacizumab extends the life 
of patients. 
Benefits, harms and treatment costs of this therapy must be weighed against 
each other accurately, especially since bevacizumab is not (yet) approved for 
the indication in question. 
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